GlobeNewsWire
22 Oct 2026, 05:00 UTC · 2h ago
Pharming Group announces third quarter 2026 revenues above market expectations
Impact · against what's priced in
Pharming Group shows strong operating leverage and revenue growth in Q3, though the tightening of full-year guidance limits the upside potential. The 21% revenue increase offset by flat operating expenses provides a positive catalyst for earnings expectations.
- PHARM+0.40
No priced-in read yet
- In context
The company demonstrated significant operating leverage with a 21% revenue increase to $117.6 million while keeping operating expenses flat at $74.6 million compared to the prior year.
Read from the article alone
